Published in Circ Res on March 02, 2007
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther (2009) 1.66
Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res (2009) 1.47
Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf) (2011) 1.43
cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther (2009) 1.22
Conserved expression and functions of PDE4 in rodent and human heart. Basic Res Cardiol (2010) 1.19
Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. Circ Res (2009) 1.03
Computational models reduce complexity and accelerate insight into cardiac signaling networks. Circ Res (2011) 1.00
Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol Sin (2008) 0.99
p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction. Circ Res (2012) 0.98
Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ Res (2012) 0.95
Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB J (2011) 0.94
PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients. Br J Pharmacol (2013) 0.87
Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury. Proc Natl Acad Sci U S A (2015) 0.86
Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. J Cardiovasc Transl Res (2010) 0.85
Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects. Horm Metab Res (2012) 0.84
PDE3 inhibition in dilated cardiomyopathy. Curr Opin Pharmacol (2011) 0.84
Osteopenia in transgenic mice with osteoblast-targeted expression of the inducible cAMP early repressor. Bone (2008) 0.83
Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis (2014) 0.81
Phosphodiesterase 3A expression is modulated by nitric oxide in rat pulmonary artery smooth muscle cells. J Physiol Pharmacol (2010) 0.80
Therapeutic potential of PDE modulation in treating heart disease. Future Med Chem (2013) 0.80
Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network. J Mol Cell Cardiol (2016) 0.79
Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2. J Biol Chem (2015) 0.78
Role of PDE3A in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: implications in cardiovascular diseases and infertility. Curr Opin Pharmacol (2011) 0.78
Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms. Proc Natl Acad Sci U S A (2013) 0.77
Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway. J Mol Cell Cardiol (2015) 0.77
Epac2-Rap1 Signaling Regulates Reactive Oxygen Species Production and Susceptibility to Cardiac Arrhythmias. Antioxid Redox Signal (2016) 0.77
β-adrenergic receptor-dependent alterations in murine cardiac transcript expression are differentially regulated by gefitinib in vivo. PLoS One (2014) 0.76
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. J Endocrinol Invest (2015) 0.76
Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation. J Biol Chem (2016) 0.75
Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (1997) 11.48
Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature (1988) 7.99
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med (1991) 6.65
Apoptosis in the failing human heart. N Engl J Med (1997) 6.35
Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest (2005) 5.48
Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science (2002) 4.96
Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet (1990) 4.59
PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell (2004) 3.87
The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature (2005) 3.82
Components of a new human protein kinase signal transduction pathway. J Biol Chem (1995) 3.78
Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem (1999) 3.42
What is the role of beta-adrenergic signaling in heart failure? Circ Res (2003) 3.22
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell (2005) 3.01
Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell (1993) 2.84
Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol (2000) 2.62
Adrenergic signals direct rhythmic expression of transcriptional repressor CREM in the pineal gland. Nature (1993) 2.61
Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res (2004) 2.58
Apoptosis and heart failure: A critical review of the literature. Circ Res (2000) 2.48
beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A (2003) 2.43
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest (2005) 2.36
Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci U S A (1996) 2.34
Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol (2000) 2.25
Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol (1999) 2.25
Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun (1995) 2.15
Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci U S A (1991) 2.15
Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci U S A (2002) 2.11
cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. Proc Natl Acad Sci U S A (1996) 2.03
Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med (1978) 2.03
Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A (1995) 1.98
Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem (1993) 1.96
IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes (2001) 1.92
Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res (2005) 1.91
Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol (1990) 1.88
Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res (2006) 1.86
Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation (1987) 1.78
Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest (2004) 1.68
Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ Res (2003) 1.66
Phosphodiesterase 4D is required for beta2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proc Natl Acad Sci U S A (2005) 1.65
Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol (1986) 1.58
A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. Circ Res (2006) 1.57
Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation (2005) 1.53
Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes. Br J Pharmacol (1999) 1.51
Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem (1997) 1.49
Insulin-like growth factor-1 and myocyte growth: the danger of a dogma. Part I. Postnatal myocardial development: normal growth. Cardiovasc Res (1996) 1.49
Akt1 in the cardiovascular system: friend or foe? J Clin Invest (2005) 1.43
Stimulation of adenosine 3',5'-monophosphate hydrolysis by guanosine 3',5'-monophosphate. J Biol Chem (1971) 1.41
Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. Circulation (2005) 1.41
High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem (1991) 1.40
Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J (1999) 1.36
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J (1999) 1.36
Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation. Blood Vessels (1991) 1.35
Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol (2001) 1.35
A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A (2005) 1.34
Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest (1995) 1.33
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev (2001) 1.29
Hydrogen peroxide stimulates c-Src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: potential role in cell survival following oxidative insults. J Biol Chem (2002) 1.27
Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes. J Physiol (2001) 1.26
Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res (2003) 1.26
Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure. N Engl J Med (1983) 1.26
Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase. Biochemistry (1984) 1.25
Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res (1987) 1.23
cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest (1997) 1.23
Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol (2005) 1.22
Inducible cAMP early repressor (ICER) in the nervous system--a transcriptional regulator of neuronal plasticity and programmed cell death. J Neurochem (2003) 1.19
BMK1 mediates growth factor-induced cell proliferation through direct cellular activation of serum and glucocorticoid-inducible kinase. J Biol Chem (2001) 1.19
Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol (1991) 1.19
Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem (2005) 1.17
Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res (2002) 1.15
Inducible cAMP early repressor, an endogenous antagonist of cAMP responsive element-binding protein, evokes neuronal apoptosis in vitro. J Neurosci (2003) 1.12
Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol (2003) 1.12
Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest (1991) 1.12
The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion. J Biol Chem (1999) 1.11
Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J Biol Chem (1987) 1.10
Identification, quantitation, and cellular localization of PDE1 calmodulin-stimulated cyclic nucleotide phosphodiesterases. Methods (1998) 1.09
Signal transduction by cGMP in heart. Basic Res Cardiol (1992) 1.09
Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem (2002) 1.08
Mitogen-activated protein kinase phosphorylates and targets inducible cAMP early repressor to ubiquitin-mediated destruction. J Biol Chem (2001) 1.05
Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. J Mol Cell Cardiol (1997) 1.05
Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following beta2-adrenergic stimulation of ICa,L in frog ventricular myocytes. J Physiol (2003) 1.05
Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue. Circ Res (1991) 1.03
Modulation of SERCA: implications for the failing human heart. Basic Res Cardiol (2002) 1.02
Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol (2001) 1.00
Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J (1993) 0.99
Amrinone relaxes potassium-induced contracture of failing right ventricular muscle of cats. J Cardiovasc Pharmacol (1983) 0.99
Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev (2005) 0.98
Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation (1997) 0.96
Activation of big MAP kinase 1 (BMK1/ERK5) inhibits cardiac injury after myocardial ischemia and reperfusion. FEBS Lett (2004) 0.96
Suppression of T cell function: a potential role for transcriptional repressor ICER. J Leukoc Biol (2000) 0.95
Degradation of the inducible cAMP early repressor (ICER) by the ubiquitin-proteasome pathway. Biochem J (1997) 0.94
Subclasses of cyclic AMP phosphodiesterase in cardiac muscle. J Mol Cell Cardiol (1987) 0.94
Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest (1985) 0.93
LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol Pharmacol (1986) 0.91
Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J (2001) 0.91
Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure. Heart Vessels (2002) 0.91
Cyclic nucleotide dependent relaxation in vascular smooth muscle. Can J Physiol Pharmacol (1994) 0.90
Effect of milrinone on left ventricular relaxation and Ca(2+) uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol (2000) 0.90
Local response of L-type Ca(2+) current to nitric oxide in frog ventricular myocytes. J Physiol (2001) 0.90
Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role for cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1. J Cardiovasc Pharmacol (1991) 0.90
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature (2016) 2.53
Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med (2009) 2.24
Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res (2008) 2.01
Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation (2007) 1.97
Flow antagonizes TNF-alpha signaling in endothelial cells by inhibiting caspase-dependent PKC zeta processing. Circ Res (2007) 1.87
Fluid shear stress activates proline-rich tyrosine kinase via reactive oxygen species-dependent pathway. Arterioscler Thromb Vasc Biol (2002) 1.79
Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium. Circulation (2006) 1.67
Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res (2009) 1.47
Inhibiting p90 ribosomal S6 kinase prevents (Na+)-H+ exchanger-mediated cardiac ischemia-reperfusion injury. Circulation (2006) 1.46
Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation (2008) 1.34
Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy. Cardiovasc Res (2002) 1.33
Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res (2003) 1.26
ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPARdelta) stimulation. J Biol Chem (2006) 1.21
Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med (2010) 1.18
Role of p90 ribosomal S6 kinase (p90RSK) in reactive oxygen species and protein kinase C beta (PKC-beta)-mediated cardiac troponin I phosphorylation. J Biol Chem (2005) 1.17
Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ Res (2007) 1.16
PKCζ mediates disturbed flow-induced endothelial apoptosis via p53 SUMOylation. J Cell Biol (2011) 1.15
BMK1/ERK5 is a novel regulator of angiogenesis by destabilizing hypoxia inducible factor 1alpha. Circ Res (2005) 1.15
Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler Thromb Vasc Biol (2012) 1.12
PKCzeta decreases eNOS protein stability via inhibitory phosphorylation of ERK5. Blood (2010) 1.07
Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res (2010) 1.06
Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction. Circ J (2011) 1.03
Reactive oxygen species-induced activation of p90 ribosomal S6 kinase prolongs cardiac repolarization through inhibiting outward K+ channel activity. Circ Res (2008) 1.02
Cardiac-specific overexpression of diacylglycerol kinase zeta prevents Gq protein-coupled receptor agonist-induced cardiac hypertrophy in transgenic mice. Circulation (2005) 1.02
MK2 SUMOylation regulates actin filament remodeling and subsequent migration in endothelial cells by inhibiting MK2 kinase and HSP27 phosphorylation. Blood (2010) 1.00
De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis. Circ Res (2013) 0.99
p90RSK targets the ERK5-CHIP ubiquitin E3 ligase activity in diabetic hearts and promotes cardiac apoptosis and dysfunction. Circ Res (2012) 0.98
Adenovirus-mediated overexpression of diacylglycerol kinase-zeta inhibits endothelin-1-induced cardiomyocyte hypertrophy. Circulation (2005) 0.97
ERK1/2 associates with the c-Met-binding domain of growth factor receptor-bound protein 2 (Grb2)-associated binder-1 (Gab1): role in ERK1/2 and early growth response factor-1 (Egr-1) nuclear accumulation. J Biol Chem (2004) 0.97
Activation of big MAP kinase 1 (BMK1/ERK5) inhibits cardiac injury after myocardial ischemia and reperfusion. FEBS Lett (2004) 0.96
Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure. Cardiovasc Res (2013) 0.93
Shear stress and atherosclerosis. Mol Cells (2014) 0.92
Inhibition of tumor necrosis factor-[alpha]-induced SHP-2 phosphatase activity by shear stress: a mechanism to reduce endothelial inflammation. Arterioscler Thromb Vasc Biol (2003) 0.88
p62 binding to protein kinase C ζ regulates tumor necrosis factor α-induced apoptotic pathway in endothelial cells. Arterioscler Thromb Vasc Biol (2012) 0.87
Cyclic nucleotide phosphodiesterase 1 regulates lysosome-dependent type I collagen protein degradation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2010) 0.87
Neural substrates of irony comprehension: A functional MRI study. Brain Res (2009) 0.85
Ca2+/calmodulin-stimulated PDE1 regulates the beta-catenin/TCF signaling through PP2A B56 gamma subunit in proliferating vascular smooth muscle cells. FEBS J (2010) 0.85
Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol (2013) 0.84
Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. J Clin Invest (2015) 0.83
Glucagon-like peptide-1 and its cardiovascular effects. Curr Atheroscler Rep (2012) 0.83
Bone morphogenetic protein (BMP) family, SMAD signaling and Id helix-loop-helix proteins in the vasculature: the continuous mystery of BMPs pleotropic effects. J Mol Cell Cardiol (2006) 0.82
Atheroprone flow activation of the sterol regulatory element binding protein 2 and nod-like receptor protein 3 inflammasome mediates focal atherosclerosis. Circulation (2013) 0.82
Protein kinase C-alpha and protein kinase C-epsilon are required for Grb2-associated binder-1 tyrosine phosphorylation in response to platelet-derived growth factor. J Biol Chem (2002) 0.82
Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity. Arterioscler Thromb Vasc Biol (2012) 0.82
Pleckstrin homology and phosphotyrosine-binding domain-dependent membrane association and tyrosine phosphorylation of Dok-4, an inhibitory adapter molecule expressed in epithelial cells. J Biol Chem (2004) 0.82
1,5-anhydro-D-fructose and its derivatives: biosynthesis, preparation and potential medical applications. Planta Med (2010) 0.81
Hypoxia and HIF-1alpha stability: another stress-sensing mechanism for Shc. Circ Res (2002) 0.78
Magnetoencephalography evidence for different brain subregions serving two musical cultures. Neuropsychologia (2012) 0.78
Cezanne paints inflammation by regulating ubiquitination. Circ Res (2013) 0.77
Preparation and reactivity of a novel disaccharide, glucosyl 1,5-anhydro-D-fructose (1,5-anhydro-3-O-alpha-glucopyranosyl-D-fructose). Carbohydr Res (2003) 0.77
NADPH oxidase in vascular injury: a new insight about its regulation and role in T cells. Circ Res (2009) 0.76
[Is the victim of irony identified by echoic mention?]. Shinrigaku Kenkyu (2010) 0.75
[The effect of L1 word reading system on L2 English word recognition: a comparison of Japanese and Chinese native speakers]. Shinrigaku Kenkyu (2008) 0.75
Fast optical channel recovery in field demonstration of 100-Gbit/s Ethernet over OTN using real-time DSP. Opt Express (2011) 0.75
Neural processing associated with comprehension of an indirect reply during a scenario reading task. Neuropsychologia (2011) 0.75